APO Research
Talk to an analyst

APO RESEARCH · REPORT

Community-acquired Bacterial Pneumonia

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Community-acquired Bacterial Pneumonia Market Analysis and Forecast 2026-2032

19 December 2025192 pages

Choose your research edition.

Industry ResearchCommunity-acquired Bacterial Pneumonia Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Community-acquired Bacterial Pneumonia Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Community-acquired Bacterial Pneumonia Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Community-acquired Bacterial Pneumonia Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Community-acquired Bacterial Pneumonia Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Community-acquired Bacterial Pneumonia market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Community-acquired Bacterial Pneumonia is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Community-acquired Bacterial Pneumonia is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Community-acquired Bacterial Pneumonia is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Community-acquired Bacterial Pneumonia is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Community-acquired Bacterial Pneumonia include Takeda Pharmaceutical Company Limited, Sanofi S.A., Mylan N.V., Pfizer Inc., Bayer AG, Paratek Pharmaceuticals, Nabriva Therapeutics, Melinta Therapeutics and Lupin Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Community-acquired Bacterial Pneumonia, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Community-acquired Bacterial Pneumonia, also provides the revenue of main regions and countries. Of the upcoming market potential for Community-acquired Bacterial Pneumonia, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Community-acquired Bacterial Pneumonia revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Community-acquired Bacterial Pneumonia market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Community-acquired Bacterial Pneumonia revenue, projected growth trends, production technology, application and end-user industry.

Community-acquired Bacterial Pneumonia Segment by Company

Takeda Pharmaceutical Company Limited

Sanofi S.A.

Mylan N.V.

Pfizer Inc.

Bayer AG

Paratek Pharmaceuticals

Nabriva Therapeutics

Melinta Therapeutics

Lupin Pharmaceuticals

Dainippon Sumitomo Pharma

Basilea Pharmaceutica International AG

Allergan plc

Community-acquired Bacterial Pneumonia Segment by Type

Oxazolidinone

Glycylcycline

Pleuromutilin Antibiotic

Ketolide

Cephalosporin

Others

Community-acquired Bacterial Pneumonia Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Community-acquired Bacterial Pneumonia Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Community-acquired Bacterial Pneumonia market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Community-acquired Bacterial Pneumonia and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Community-acquired Bacterial Pneumonia.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Community-acquired Bacterial Pneumonia in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Community-acquired Bacterial Pneumonia company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Community-acquired Bacterial Pneumonia revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Community-acquired Bacterial Pneumonia Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oxazolidinone Major Player Table 3. Glycylcycline Major Player Table 4. Pleuromutilin Antibiotic Major Player Table 5. Ketolide Major Player Table 6. Cephalosporin Major Player Table 7. Others Major Player Table 8. Global Community-acquired Bacterial Pneumonia Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Retail Pharmacies Major Player Table 10. Online Pharmacies Major Player Table 11. Hospital Pharmacies Major Player Table 12. Community-acquired Bacterial Pneumonia Industry Trends Table 13. Community-acquired Bacterial Pneumonia Industry Drivers Table 14. Community-acquired Bacterial Pneumonia Industry Opportunities and Challenges Table 15. Community-acquired Bacterial Pneumonia Industry Restraints Table 16. Global Community-acquired Bacterial Pneumonia Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Community-acquired Bacterial Pneumonia Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Community-acquired Bacterial Pneumonia Market Share by Region (2021-2026) Table 19. Global Community-acquired Bacterial Pneumonia Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Community-acquired Bacterial Pneumonia Market Share by Region (2027-2032) Table 21. Global Community-acquired Bacterial Pneumonia Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Players (2021-2026) Table 23. Global Community-acquired Bacterial Pneumonia Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Community-acquired Bacterial Pneumonia Key Players Headquarters & Area Served Table 25. Global Community-acquired Bacterial Pneumonia Players, Product Type & Application Table 26. Global Community-acquired Bacterial Pneumonia Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Community-acquired Bacterial Pneumonia by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Community-acquired Bacterial Pneumonia Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Community-acquired Bacterial Pneumonia Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Community-acquired Bacterial Pneumonia Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2021-2026) Table 33. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2027-2032) Table 34. Global Community-acquired Bacterial Pneumonia Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Community-acquired Bacterial Pneumonia Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Community-acquired Bacterial Pneumonia Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2021-2026) Table 38. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2027-2032) Table 39. Takeda Pharmaceutical Company Limited Company Information Table 40. Takeda Pharmaceutical Company Limited Business Overview Table 41. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product Portfolio Table 43. Takeda Pharmaceutical Company Limited Recent Development Table 44. Sanofi S.A. Company Information Table 45. Sanofi S.A. Business Overview Table 46. Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Sanofi S.A. Community-acquired Bacterial Pneumonia Product Portfolio Table 48. Sanofi S.A. Recent Development Table 49. Mylan N.V. Company Information Table 50. Mylan N.V. Business Overview Table 51. Mylan N.V. Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Mylan N.V. Community-acquired Bacterial Pneumonia Product Portfolio Table 53. Mylan N.V. Recent Development Table 54. Pfizer Inc. Company Information Table 55. Pfizer Inc. Business Overview Table 56. Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Pfizer Inc. Community-acquired Bacterial Pneumonia Product Portfolio Table 58. Pfizer Inc. Recent Development Table 59. Bayer AG Company Information Table 60. Bayer AG Business Overview Table 61. Bayer AG Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Bayer AG Community-acquired Bacterial Pneumonia Product Portfolio Table 63. Bayer AG Recent Development Table 64. Paratek Pharmaceuticals Company Information Table 65. Paratek Pharmaceuticals Business Overview Table 66. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product Portfolio Table 68. Paratek Pharmaceuticals Recent Development Table 69. Nabriva Therapeutics Company Information Table 70. Nabriva Therapeutics Business Overview Table 71. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product Portfolio Table 73. Nabriva Therapeutics Recent Development Table 74. Melinta Therapeutics Company Information Table 75. Melinta Therapeutics Business Overview Table 76. Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Melinta Therapeutics Community-acquired Bacterial Pneumonia Product Portfolio Table 78. Melinta Therapeutics Recent Development Table 79. Lupin Pharmaceuticals Company Information Table 80. Lupin Pharmaceuticals Business Overview Table 81. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product Portfolio Table 83. Lupin Pharmaceuticals Recent Development Table 84. Dainippon Sumitomo Pharma Company Information Table 85. Dainippon Sumitomo Pharma Business Overview Table 86. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product Portfolio Table 88. Dainippon Sumitomo Pharma Recent Development Table 89. Basilea Pharmaceutica International AG Company Information Table 90. Basilea Pharmaceutica International AG Business Overview Table 91. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product Portfolio Table 93. Basilea Pharmaceutica International AG Recent Development Table 94. Allergan plc Company Information Table 95. Allergan plc Business Overview Table 96. Allergan plc Community-acquired Bacterial Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Allergan plc Community-acquired Bacterial Pneumonia Product Portfolio Table 98. Allergan plc Recent Development Table 99. North America Community-acquired Bacterial Pneumonia Revenue by Type (2021-2026) & (US$ Million) Table 100. North America Community-acquired Bacterial Pneumonia Revenue by Type (2027-2032) & (US$ Million) Table 101. North America Community-acquired Bacterial Pneumonia Revenue by Application (2021-2026) & (US$ Million) Table 102. North America Community-acquired Bacterial Pneumonia Revenue by Application (2027-2032) & (US$ Million) Table 103. North America Community-acquired Bacterial Pneumonia Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. North America Community-acquired Bacterial Pneumonia Revenue by Country (2021-2026) & (US$ Million) Table 105. North America Community-acquired Bacterial Pneumonia Revenue by Country (US$ Million) & (2027-2032) Table 106. Europe Community-acquired Bacterial Pneumonia Revenue by Type (2021-2026) & (US$ Million) Table 107. Europe Community-acquired Bacterial Pneumonia Revenue by Type (2027-2032) & (US$ Million) Table 108. Europe Community-acquired Bacterial Pneumonia Revenue by Application (2021-2026) & (US$ Million) Table 109. Europe Community-acquired Bacterial Pneumonia Revenue by Application (2027-2032) & (US$ Million) Table 110. Europe Community-acquired Bacterial Pneumonia Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 111. Europe Community-acquired Bacterial Pneumonia Revenue by Country (2021-2026) & (US$ Million) Table 112. Europe Community-acquired Bacterial Pneumonia Revenue by Country (US$ Million) & (2027-2032) Table 113. China Community-acquired Bacterial Pneumonia Revenue by Type (2021-2026) & (US$ Million) Table 114. China Community-acquired Bacterial Pneumonia Revenue by Type (2027-2032) & (US$ Million) Table 115. China Community-acquired Bacterial Pneumonia Revenue by Application (2021-2026) & (US$ Million) Table 116. China Community-acquired Bacterial Pneumonia Revenue by Application (2027-2032) & (US$ Million) Table 117. Asia Community-acquired Bacterial Pneumonia Revenue by Type (2021-2026) & (US$ Million) Table 118. Asia Community-acquired Bacterial Pneumonia Revenue by Type (2027-2032) & (US$ Million) Table 119. Asia Community-acquired Bacterial Pneumonia Revenue by Application (2021-2026) & (US$ Million) Table 120. Asia Community-acquired Bacterial Pneumonia Revenue by Application (2027-2032) & (US$ Million) Table 121. Asia Community-acquired Bacterial Pneumonia Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 122. Asia Community-acquired Bacterial Pneumonia Revenue by Region (US$ Million) & (2021-2026) Table 123. Asia Community-acquired Bacterial Pneumonia Revenue by Region (US$ Million) & (2027-2032) Table 124. SAMEA Community-acquired Bacterial Pneumonia Revenue by Type (2021-2026) & (US$ Million) Table 125. SAMEA Community-acquired Bacterial Pneumonia Revenue by Type (2027-2032) & (US$ Million) Table 126. SAMEA Community-acquired Bacterial Pneumonia Revenue by Application (2021-2026) & (US$ Million) Table 127. SAMEA Community-acquired Bacterial Pneumonia Revenue by Application (2027-2032) & (US$ Million) Table 128. SAMEA Community-acquired Bacterial Pneumonia Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 129. SAMEA Community-acquired Bacterial Pneumonia Revenue by Country (2021-2026) & (US$ Million) Table 130. SAMEA Community-acquired Bacterial Pneumonia Revenue by Country (US$ Million) & (2027-2032) Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Community-acquired Bacterial Pneumonia Image Figure 2. Global Community-acquired Bacterial Pneumonia Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Community-acquired Bacterial Pneumonia Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oxazolidinone Image Figure 5. Glycylcycline Image Figure 6. Pleuromutilin Antibiotic Image Figure 7. Ketolide Image Figure 8. Cephalosporin Image Figure 9. Others Image Figure 10. Global Community-acquired Bacterial Pneumonia Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Community-acquired Bacterial Pneumonia Market Size Share 2021 VS 2025 VS 2032 Figure 12. Retail Pharmacies Image Figure 13. Online Pharmacies Image Figure 14. Hospital Pharmacies Image Figure 15. Global Community-acquired Bacterial Pneumonia Market Size (US$ Million) & (2021-2032) Figure 16. Global Community-acquired Bacterial Pneumonia Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Community-acquired Bacterial Pneumonia Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Community-acquired Bacterial Pneumonia Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Community-acquired Bacterial Pneumonia Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Community-acquired Bacterial Pneumonia Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2021-2032) Figure 23. Global Community-acquired Bacterial Pneumonia Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2021-2032) Figure 26. North America Community-acquired Bacterial Pneumonia Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Community-acquired Bacterial Pneumonia Revenue Share by Type (2021-2032) Figure 28. North America Community-acquired Bacterial Pneumonia Revenue Share by Application (2021-2032) Figure 29. North America Community-acquired Bacterial Pneumonia Revenue Share by Country (2021-2032) Figure 30. United States Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Community-acquired Bacterial Pneumonia Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Community-acquired Bacterial Pneumonia Revenue Share by Type (2021-2032) Figure 35. Europe Community-acquired Bacterial Pneumonia Revenue Share by Application (2021-2032) Figure 36. Europe Community-acquired Bacterial Pneumonia Revenue Share by Country (2021-2032) Figure 37. Germany Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Community-acquired Bacterial Pneumonia Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Community-acquired Bacterial Pneumonia Revenue Share by Type (2021-2032) Figure 47. China Community-acquired Bacterial Pneumonia Revenue Share by Application (2021-2032) Figure 48. Asia Community-acquired Bacterial Pneumonia Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Community-acquired Bacterial Pneumonia Revenue Share by Type (2021-2032) Figure 50. Asia Community-acquired Bacterial Pneumonia Revenue Share by Application (2021-2032) Figure 51. Asia Community-acquired Bacterial Pneumonia Revenue Share by Region (2021-2032) Figure 52. Japan Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Community-acquired Bacterial Pneumonia Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Community-acquired Bacterial Pneumonia Revenue Share by Type (2021-2032) Figure 60. SAMEA Community-acquired Bacterial Pneumonia Revenue Share by Application (2021-2032) Figure 61. SAMEA Community-acquired Bacterial Pneumonia Revenue Share by Country (2021-2032) Figure 62. Brazil Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Community-acquired Bacterial Pneumonia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Oxazolidinone
  • Glycylcycline
  • Pleuromutilin Antibiotic
  • Ketolide
  • Cephalosporin
  • Others
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Takeda Pharmaceutical Company Limited
  • Sanofi S.A.
  • Mylan N.V.
  • Pfizer Inc.
  • Bayer AG
  • Paratek Pharmaceuticals
  • Nabriva Therapeutics
  • Melinta Therapeutics
  • Lupin Pharmaceuticals
  • Dainippon Sumitomo Pharma
  • Basilea Pharmaceutica International AG
  • Allergan plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Community-acquired Bacterial Pneumonia Market by Type
  3. 1.2.1 Global Community-acquired Bacterial Pneumonia Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oxazolidinone
  5. 1.2.3 Glycylcycline
  6. 1.2.4 Pleuromutilin Antibiotic
  7. 1.2.5 Ketolide
  8. 1.2.6 Cephalosporin
  9. 1.2.7 Others
  10. 1.3 Community-acquired Bacterial Pneumonia Market by Application
  11. 1.3.1 Global Community-acquired Bacterial Pneumonia Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Retail Pharmacies
  13. 1.3.3 Online Pharmacies
  14. 1.3.4 Hospital Pharmacies
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Community-acquired Bacterial Pneumonia Market Dynamics
  1. 2.1 Community-acquired Bacterial Pneumonia Industry Trends
  2. 2.2 Community-acquired Bacterial Pneumonia Industry Drivers
  3. 2.3 Community-acquired Bacterial Pneumonia Industry Opportunities and Challenges
  4. 2.4 Community-acquired Bacterial Pneumonia Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Community-acquired Bacterial Pneumonia Market Perspective (2021-2032)
  2. 3.2 Global Community-acquired Bacterial Pneumonia Growth Trends by Region
  3. 3.2.1 Global Community-acquired Bacterial Pneumonia Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Community-acquired Bacterial Pneumonia Market Size by Region (2021-2026)
  5. 3.2.3 Global Community-acquired Bacterial Pneumonia Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Community-acquired Bacterial Pneumonia Revenue by Players
  2. 4.1.1 Global Community-acquired Bacterial Pneumonia Revenue by Players (2021-2026)
  3. 4.1.2 Global Community-acquired Bacterial Pneumonia Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Community-acquired Bacterial Pneumonia Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Community-acquired Bacterial Pneumonia Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Community-acquired Bacterial Pneumonia Key Players Headquarters & Area Served
  7. 4.4 Global Community-acquired Bacterial Pneumonia Players, Product Type & Application
  8. 4.5 Global Community-acquired Bacterial Pneumonia Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Community-acquired Bacterial Pneumonia Market CR5 and HHI
  11. 4.6.3 2025 Community-acquired Bacterial Pneumonia Tier 1, Tier 2, and Tier 3
5 Community-acquired Bacterial Pneumonia Market Size by Type
  1. 5.1 Global Community-acquired Bacterial Pneumonia Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Community-acquired Bacterial Pneumonia Revenue by Type (2021-2032)
  3. 5.3 Global Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2021-2032)
6 Community-acquired Bacterial Pneumonia Market Size by Application
  1. 6.1 Global Community-acquired Bacterial Pneumonia Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Community-acquired Bacterial Pneumonia Revenue by Application (2021-2032)
  3. 6.3 Global Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda Pharmaceutical Company Limited
  2. 7.1.1 Takeda Pharmaceutical Company Limited Company Information
  3. 7.1.2 Takeda Pharmaceutical Company Limited Business Overview
  4. 7.1.3 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product Portfolio
  6. 7.1.5 Takeda Pharmaceutical Company Limited Recent Developments
  7. 7.2 Sanofi S.A.
  8. 7.2.1 Sanofi S.A. Company Information
  9. 7.2.2 Sanofi S.A. Business Overview
  10. 7.2.3 Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi S.A. Community-acquired Bacterial Pneumonia Product Portfolio
  12. 7.2.5 Sanofi S.A. Recent Developments
  13. 7.3 Mylan N.V.
  14. 7.3.1 Mylan N.V. Company Information
  15. 7.3.2 Mylan N.V. Business Overview
  16. 7.3.3 Mylan N.V. Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Mylan N.V. Community-acquired Bacterial Pneumonia Product Portfolio
  18. 7.3.5 Mylan N.V. Recent Developments
  19. 7.4 Pfizer Inc.
  20. 7.4.1 Pfizer Inc. Company Information
  21. 7.4.2 Pfizer Inc. Business Overview
  22. 7.4.3 Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer Inc. Community-acquired Bacterial Pneumonia Product Portfolio
  24. 7.4.5 Pfizer Inc. Recent Developments
  25. 7.5 Bayer AG
  26. 7.5.1 Bayer AG Company Information
  27. 7.5.2 Bayer AG Business Overview
  28. 7.5.3 Bayer AG Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Bayer AG Community-acquired Bacterial Pneumonia Product Portfolio
  30. 7.5.5 Bayer AG Recent Developments
  31. 7.6 Paratek Pharmaceuticals
  32. 7.6.1 Paratek Pharmaceuticals Company Information
  33. 7.6.2 Paratek Pharmaceuticals Business Overview
  34. 7.6.3 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product Portfolio
  36. 7.6.5 Paratek Pharmaceuticals Recent Developments
  37. 7.7 Nabriva Therapeutics
  38. 7.7.1 Nabriva Therapeutics Company Information
  39. 7.7.2 Nabriva Therapeutics Business Overview
  40. 7.7.3 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product Portfolio
  42. 7.7.5 Nabriva Therapeutics Recent Developments
  43. 7.8 Melinta Therapeutics
  44. 7.8.1 Melinta Therapeutics Company Information
  45. 7.8.2 Melinta Therapeutics Business Overview
  46. 7.8.3 Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Melinta Therapeutics Community-acquired Bacterial Pneumonia Product Portfolio
  48. 7.8.5 Melinta Therapeutics Recent Developments
  49. 7.9 Lupin Pharmaceuticals
  50. 7.9.1 Lupin Pharmaceuticals Company Information
  51. 7.9.2 Lupin Pharmaceuticals Business Overview
  52. 7.9.3 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product Portfolio
  54. 7.9.5 Lupin Pharmaceuticals Recent Developments
  55. 7.10 Dainippon Sumitomo Pharma
  56. 7.10.1 Dainippon Sumitomo Pharma Company Information
  57. 7.10.2 Dainippon Sumitomo Pharma Business Overview
  58. 7.10.3 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product Portfolio
  60. 7.10.5 Dainippon Sumitomo Pharma Recent Developments
  61. 7.11 Basilea Pharmaceutica International AG
  62. 7.11.1 Basilea Pharmaceutica International AG Company Information
  63. 7.11.2 Basilea Pharmaceutica International AG Business Overview
  64. 7.11.3 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product Portfolio
  66. 7.11.5 Basilea Pharmaceutica International AG Recent Developments
  67. 7.12 Allergan plc
  68. 7.12.1 Allergan plc Company Information
  69. 7.12.2 Allergan plc Business Overview
  70. 7.12.3 Allergan plc Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Allergan plc Community-acquired Bacterial Pneumonia Product Portfolio
  72. 7.12.5 Allergan plc Recent Developments
8 North America
  1. 8.1 North America Community-acquired Bacterial Pneumonia Revenue (2021-2032)
  2. 8.2 North America Community-acquired Bacterial Pneumonia Revenue by Type (2021-2032)
  3. 8.2.1 North America Community-acquired Bacterial Pneumonia Revenue by Type (2021-2026)
  4. 8.2.2 North America Community-acquired Bacterial Pneumonia Revenue by Type (2027-2032)
  5. 8.3 North America Community-acquired Bacterial Pneumonia Revenue Share by Type (2021-2032)
  6. 8.4 North America Community-acquired Bacterial Pneumonia Revenue by Application (2021-2032)
  7. 8.4.1 North America Community-acquired Bacterial Pneumonia Revenue by Application (2021-2026)
  8. 8.4.2 North America Community-acquired Bacterial Pneumonia Revenue by Application (2027-2032)
  9. 8.5 North America Community-acquired Bacterial Pneumonia Revenue Share by Application (2021-2032)
  10. 8.6 North America Community-acquired Bacterial Pneumonia Revenue by Country
  11. 8.6.1 North America Community-acquired Bacterial Pneumonia Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Community-acquired Bacterial Pneumonia Revenue by Country (2021-2026)
  13. 8.6.3 North America Community-acquired Bacterial Pneumonia Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Community-acquired Bacterial Pneumonia Revenue (2021-2032)
  2. 9.2 Europe Community-acquired Bacterial Pneumonia Revenue by Type (2021-2032)
  3. 9.2.1 Europe Community-acquired Bacterial Pneumonia Revenue by Type (2021-2026)
  4. 9.2.2 Europe Community-acquired Bacterial Pneumonia Revenue by Type (2027-2032)
  5. 9.3 Europe Community-acquired Bacterial Pneumonia Revenue Share by Type (2021-2032)
  6. 9.4 Europe Community-acquired Bacterial Pneumonia Revenue by Application (2021-2032)
  7. 9.4.1 Europe Community-acquired Bacterial Pneumonia Revenue by Application (2021-2026)
  8. 9.4.2 Europe Community-acquired Bacterial Pneumonia Revenue by Application (2027-2032)
  9. 9.5 Europe Community-acquired Bacterial Pneumonia Revenue Share by Application (2021-2032)
  10. 9.6 Europe Community-acquired Bacterial Pneumonia Revenue by Country
  11. 9.6.1 Europe Community-acquired Bacterial Pneumonia Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Community-acquired Bacterial Pneumonia Revenue by Country (2021-2026)
  13. 9.6.3 Europe Community-acquired Bacterial Pneumonia Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Community-acquired Bacterial Pneumonia Revenue (2021-2032)
  2. 10.2 China Community-acquired Bacterial Pneumonia Revenue by Type (2021-2032)
  3. 10.2.1 China Community-acquired Bacterial Pneumonia Revenue by Type (2021-2026)
  4. 10.2.2 China Community-acquired Bacterial Pneumonia Revenue by Type (2027-2032)
  5. 10.3 China Community-acquired Bacterial Pneumonia Revenue Share by Type (2021-2032)
  6. 10.4 China Community-acquired Bacterial Pneumonia Revenue by Application (2021-2032)
  7. 10.4.1 China Community-acquired Bacterial Pneumonia Revenue by Application (2021-2026)
  8. 10.4.2 China Community-acquired Bacterial Pneumonia Revenue by Application (2027-2032)
  9. 10.5 China Community-acquired Bacterial Pneumonia Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Community-acquired Bacterial Pneumonia Revenue (2021-2032)
  2. 11.2 Asia Community-acquired Bacterial Pneumonia Revenue by Type (2021-2032)
  3. 11.2.1 Asia Community-acquired Bacterial Pneumonia Revenue by Type (2021-2026)
  4. 11.2.2 Asia Community-acquired Bacterial Pneumonia Revenue by Type (2027-2032)
  5. 11.3 Asia Community-acquired Bacterial Pneumonia Revenue Share by Type (2021-2032)
  6. 11.4 Asia Community-acquired Bacterial Pneumonia Revenue by Application (2021-2032)
  7. 11.4.1 Asia Community-acquired Bacterial Pneumonia Revenue by Application (2021-2026)
  8. 11.4.2 Asia Community-acquired Bacterial Pneumonia Revenue by Application (2027-2032)
  9. 11.5 Asia Community-acquired Bacterial Pneumonia Revenue Share by Application (2021-2032)
  10. 11.6 Asia Community-acquired Bacterial Pneumonia Revenue by Country
  11. 11.6.1 Asia Community-acquired Bacterial Pneumonia Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Community-acquired Bacterial Pneumonia Revenue by Country (2021-2026)
  13. 11.6.3 Asia Community-acquired Bacterial Pneumonia Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Community-acquired Bacterial Pneumonia Revenue (2021-2032)
  2. 12.2 SAMEA Community-acquired Bacterial Pneumonia Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Community-acquired Bacterial Pneumonia Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Community-acquired Bacterial Pneumonia Revenue by Type (2027-2032)
  5. 12.3 SAMEA Community-acquired Bacterial Pneumonia Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Community-acquired Bacterial Pneumonia Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Community-acquired Bacterial Pneumonia Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Community-acquired Bacterial Pneumonia Revenue by Application (2027-2032)
  9. 12.5 SAMEA Community-acquired Bacterial Pneumonia Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Community-acquired Bacterial Pneumonia Revenue by Country
  11. 12.6.1 SAMEA Community-acquired Bacterial Pneumonia Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Community-acquired Bacterial Pneumonia Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Community-acquired Bacterial Pneumonia Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst